國立虎尾科技大學 |

The Prostate Cancer Dilemma = Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The Prostate Cancer Dilemma/ edited by Nelson N. Stone, E. David Crawford.
Reminder of title:	Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy /
other author:	Stone, Nelson N.
Description:	XIV, 206 p. 55 illus., 49 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Urology. -
Online resource:	https://doi.org/10.1007/978-3-319-21485-6
ISBN:	9783319214856

The Prostate Cancer Dilemma = Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy /
The Prostate Cancer DilemmaSelecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy /[electronic resource] :edited by Nelson N. Stone, E. David Crawford. - 1st ed. 2016. - XIV, 206 p. 55 illus., 49 illus. in color.online resource.

Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.

This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.

ISBN: 9783319214856

Standard No.: 10.1007/978-3-319-21485-6doiSubjects--Topical Terms:

645258
Urology.

LC Class. No.: RC870-923.2

Dewey Class. No.: 616.6

The Prostate Cancer Dilemma = Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy /
LDR:03770nam a22004095i 4500 001 981403
003 DE-He213
005 20200630100624.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319214856 $9 978-3-319-21485-6
024 7 $a 10.1007/978-3-319-21485-6 $2 doi
035 $a 978-3-319-21485-6
050 4 $a RC870-923.2
050 4 $a RC875-899.5
072 7 $a MJS $2 bicssc
072 7 $a MED088000 $2 bisacsh
072 7 $a MJS $2 thema
082 0 4 $a 616.6 $2 23
245 1 4 $a The Prostate Cancer Dilemma $h [electronic resource] : $b Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy / $c edited by Nelson N. Stone, E. David Crawford.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XIV, 206 p. 55 illus., 49 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.
520 $a This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.
650 0 $a Urology. $3 645258
650 0 $a Oncology . $3 1253469
650 0 $a Pathology. $3 668553
650 2 4 $a Oncology. $3 593951
700 1 $a Stone, Nelson N. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103117
700 1 $a Crawford, E. David. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103118
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319214849
776 0 8 $i Printed edition: $z 9783319214863
776 0 8 $i Printed edition: $z 9783319364438
856 4 0 $u https://doi.org/10.1007/978-3-319-21485-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)